This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colao, A. Articles by Lombardi, G. Search for Related Content PubMed PubMed Citation Articles by Colao, A. Articles by Lombardi, G.

The Cardiovascular Risk of GH-Deficient Adolescents

Departments of Molecular and Clinical Endocrinology and Oncology (A.C., C.D.S., F.O., G.L.), Pediatrics (M.S.), and Internal Medicine I (L.S.), University Federico II of Naples, 80131 Naples, Italy

Address all correspondence and requests for reprints to: Annamaria Colao, M.D., Ph.D., Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S. Pansini 5, 80131 Naples, Italy. E-mail: . colao{at}unina.it

Abstract

To investigate the onset of the cardiovascular impairment in patients with GH deficiency (GHD), we prospectively studied cardiovascular risk parameters, cardiac mass and performance (by echocardiography) in 10 adolescent patients (5 with isolated GHD and 5 with multiple GHD) who reached their final height before GH replacement withdrawal, 6 months after GH replacement withdrawal, and 6 months after GH treatment was restarted, and in 10 sex- and age-matched controls.

At study entry, when compared with controls, GHD adolescents had lower IGF-I levels (although still in the normal age range) and high-density lipoprotein (HDL)-cholesterol levels, higher total/HDL-cholesterol ratio, lower triglyceride levels, higher fibrinogen levels, and lower heart rate, systolic blood pressure, and early-to-late mitral flow velocity ratio (E/A). Left ventricular (LV) mass index and ejection fraction were normal. Six months after GH withdrawal, IGF-I levels decreased remarkably in all cases (from 176.6 ± 8.3 to 77.5 ± 8.9 µg/liter; P < 0.001), whereas low-density lipoprotein-cholesterol and triglyceride levels significantly increased. The total/HDL-cholesterol ratio (from 3.89 ± 0.1 to 4.74 ± 0.2; P < 0.05) and fibrinogen levels (from 261 ± 7.1 to 287.5 ± 6.4 mg/dl; P < 0.05) also significantly increased compared with study entry, without any change in the other parameters. In contrast, both LV mass index (from 94.2 ± 1.6 to 87.8 ± 1.7 g/m²; P = 0.05) and E/A (from 1.32 ± 0.05 to 1.12 ± 0.03; P < 0.01) decreased, although remaining in the normal range. Six months after restarting GH replacement (at a median dose of 10 µg/kg·d), lipid and cardiac parameters were brought back to the levels measured at study entry, but in no patient did IGF-I levels reach the 50th centile for age. HDL-cholesterol levels (P < 0.0001), heart rate (P < 0.05), systolic blood pressure (P < 0.01), LV ejection fraction (P < 0.005), and E/A (P < 0.0001) remained lower, whereas total/HDL-cholesterol ratio (P < 0.01), triglycerides, and fibrinogen levels (P < 0.05) remained higher than controls.

In conclusion, GH discontinuation is inappropriate in adolescents with severe GHD, inducing impairment of lipid profile and cardiac morphology and performance. Because the results on the cardiovascular system and on the lipid profile were suboptimal, it is likely that the GH dose in severe GHD adolescents should be higher.

This article has been cited by other articles:

				K. Stochholm, T. Laursen, A. Green, P. Laurberg, M. Andersen, L. O. Kristensen, U. Feldt-Rasmussen, J. S. Christiansen, M. Frydenberg, and C. H. Gravholt Morbidity and GH deficiency: a nationwide study. Eur. J. Endocrinol., April 1, 2008; 158(4): 447 - 457. [Abstract] [Full Text] [PDF]

				M. E. Molitch, D. R. Clemmons, S. Malozowski, G. R. Merriam, S. M. Shalet, M. L. Vance, and for The Endocrine Society's Clinical Guidelines Su Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1621 - 1634. [Abstract] [Full Text] [PDF]

				M. Salerno, V. Esposito, V. Farina, G. Radetti, A. Umbaldo, D. Capalbo, L. Spinelli, S. Muzzica, G. Lombardi, and A. Colao Improvement of Cardiac Performance and Cardiovascular Risk Factors in Children with GH Deficiency after Two Years of GH Replacement Therapy: An Observational, Open, Prospective, Case-Control Study J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1288 - 1295. [Abstract] [Full Text] [PDF]

				N. Mauras, O. H. Pescovitz, V. Allada, M. Messig, M. P. Wajnrajch, B. Lippe, and on behalf of the Transition Study Group Limited Efficacy of Growth Hormone (GH) during Transition of GH-Deficient Patients from Adolescence to Adulthood: A Phase III Multicenter, Double-Blind, Randomized Two-Year Trial J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3946 - 3955. [Abstract] [Full Text] [PDF]

				S. E. Lipshultz, S. A. Vlach, S. R. Lipsitz, S. E. Sallan, M. L. Schwartz, and S. D. Colan Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines Pediatrics, June 1, 2005; 115(6): 1613 - 1622. [Abstract] [Full Text] [PDF]

				A. Colao, C. Di Somma, F. Rota, S. Di Maio, M. Salerno, A. Klain, S. Spiezia, and G. Lombardi Common Carotid Intima-Media Thickness in Growth Hormone (GH)-Deficient Adolescents: A Prospective Study after GH Withdrawal and Restarting GH Replacement J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2659 - 2665. [Abstract] [Full Text] [PDF]

				A. Colao, C. Di Somma, F. Rota, R. Pivonello, M. C. Savanelli, S. Spiezia, and G. Lombardi Short-Term Effects of Growth Hormone (GH) Treatment or Deprivation on Cardiovascular Risk Parameters and Intima-Media Thickness at Carotid Arteries in Patients with Severe GH Deficiency J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2056 - 2062. [Abstract] [Full Text] [PDF]

				P E Clayton, R C Cuneo, A Juul, J P Monson, S M Shalet, and M Tauber Consensus statement on the management of the GH-treated adolescent in the transition to adult care Eur. J. Endocrinol., February 1, 2005; 152(2): 165 - 170. [Abstract] [Full Text] [PDF]

				F. Reis, M. V. Campos, M. Bastos, L. Almeida, M. Lourenco, C. A. Ferrer-Antunes, A. Palmeiro, J. D. Santos-Dias, J. F. Mesquita, M. Carvalheiro, et al. Platelet Hyperactivation in Maintained Growth Hormone-Deficient Childhood Patients after Therapy Withdrawal as a Putative Earlier Marker of Increased Cardiovascular Risk J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 98 - 105. [Abstract] [Full Text] [PDF]

				A. Colao, C. Di Somma, A. Cuocolo, M. Filippella, F. Rota, W. Acampa, S. Savastano, M. Salvatore, and G. Lombardi The Severity of Growth Hormone Deficiency Correlates with the Severity of Cardiac Impairment in 100 Adult Patients with Hypopituitarism: An Observational, Case-Control Study J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5998 - 6004. [Abstract] [Full Text] [PDF]

				K. Link, C. Moell, S. Garwicz, E. Cavallin-Stahl, J. Bjork, U. Thilen, B. Ahren, and E. M. Erfurth Growth Hormone Deficiency Predicts Cardiovascular Risk in Young Adults Treated for Acute Lymphoblastic Leukemia in Childhood J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5003 - 5012. [Abstract] [Full Text] [PDF]

				K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho Estrogen Regulation of Growth Hormone Action Endocr. Rev., October 1, 2004; 25(5): 693 - 721. [Abstract] [Full Text] [PDF]

				A. M. Boot Body Composition and Bone Mineral Density in Adolescents with Partial Growth Hormone Deficiency J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5099 - 5100. [Full Text] [PDF]

				D. I. Shulman, A. W. Root, F. B. Diamond, B. B. Bercu, R. Martinez, and R. J. Boucek Jr. Effects of One Year of Recombinant Human Growth Hormone (GH) Therapy on Cardiac Mass and Function in Children with Classical GH Deficiency J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4095 - 4099. [Abstract] [Full Text] [PDF]